Early research (Phase 1)Study completedNCT01185873What this trial is testingDanoprevir in Healthy Volunteers And Patients With Hepatic ImpairmentWho this might be right forHealthy Volunteer Hoffmann-La Roche 81
Early research (Phase 1)Study completedNCT01565902What this trial is testingPharmacokinetics of BAF312 in Patients With Hepatic ImpairmentWho this might be right forHepatic Impairment Novartis Pharmaceuticals 40
Early research (Phase 1)Study completedNCT05537142What this trial is testingAssess the Phamacokinetics of BV100 in Participants with Varying Degrees of Hepatic ImpairmentWho this might be right forHealthy Participants BioVersys AG 33
Early research (Phase 1)Study completedNCT01600976What this trial is testingAssess Safety and Pharmacokinetics of Telaprevir in Patients With Hepatic ImpairmentWho this might be right forHepatic Impairment Janssen Infectious Diseases BVBA 24
Early research (Phase 1)Study completedNCT04154774What this trial is testingApalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic FunctionWho this might be right forHepatic Impairment Janssen Research & Development, LLC 18
Early research (Phase 1)Looking for participantsNCT06911320What this trial is testingStudy of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic FunctionWho this might be right forHealthy Volunteer StudyHepatic ImpairmentRenal Impairment Atea Pharmaceuticals, Inc. 28
Early research (Phase 1)Ended earlyNCT05209295What this trial is testingEvaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid MalignanciesWho this might be right forHepatic InsufficiencyNeoplasms Bristol-Myers Squibb 2
Early research (Phase 1)Study completedNCT06952634What this trial is testingAn Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver DamageWho this might be right forHepatic Impairment Alumis Inc 32
Early research (Phase 1)Study completedNCT00698464What this trial is testingPharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic FunctionWho this might be right forHepatic CirrhosisAlcoholism Novartis Pharmaceuticals 34
Early research (Phase 1)Ended earlyNCT04241835What this trial is testingCompare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver FunctionWho this might be right forHepatic ImpairmentAdvanced Malignant Solid Tumor Epizyme, Inc. 18
Early research (Phase 1)Study completedNCT01817985What this trial is testingEvaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic ImpairmentWho this might be right forChronic Hepatitis C Gilead Sciences 33
Early research (Phase 1)Study completedNCT03341884What this trial is testingIpatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy ParticipantsWho this might be right forHepatic Insufficiency Genentech, Inc. 29
Early research (Phase 1)WithdrawnNCT04759846What this trial is testingHepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF MelanomaWho this might be right forBRAF V600 MutationUnresectable MelanomaMetastatic Melanoma+1 more Pierre Fabre Medicament
Early research (Phase 1)Study completedNCT02683577What this trial is testingStudy to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy SubjectsWho this might be right forHepatic Impairment Ipsen 24
Early research (Phase 1)Study completedNCT03814005What this trial is testingPevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver ProblemsWho this might be right forMyelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute+3 more Takeda 17
Early research (Phase 1)Looking for participantsNCT07165002What this trial is testingThe Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver ImpairmentWho this might be right forHealthyHepatic Insufficiency Eli Lilly and Company 32
Early research (Phase 1)Study completedNCT05882032What this trial is testingLY3502970 in Participants With Impaired and Normal Liver FunctionWho this might be right forHealthyHepatic Insufficiency Eli Lilly and Company 29
Early research (Phase 1)Study completedNCT06812780What this trial is testingInvestigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389Who this might be right forHepatic Impairment AstraZeneca 35
Early research (Phase 1)Study completedNCT03713242What this trial is testingEvaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic ImpairmentWho this might be right forHepatic Impairment Idorsia Pharmaceuticals Ltd. 32
Early research (Phase 1)Looking for participantsNCT07231991What this trial is testingLearn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver FunctionWho this might be right forHealthy Participants Pfizer 24